Imagion Biosystems (ASX:IBX) FCF Margin % : -363.81% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Imagion Biosystems's Free Cash Flow for the six months ended in Dec. 2023 was A$-2.46 Mil. Imagion Biosystems's Revenue for the six months ended in Dec. 2023 was A$0.68 Mil. Therefore, Imagion Biosystems's FCF Margin % for the quarter that ended in Dec. 2023 was -363.81%.

As of today, Imagion Biosystems's current FCF Yield % is -302.96%.

The historical rank and industry rank for Imagion Biosystems's FCF Margin % or its related term are showing as below:

ASX:IBX' s FCF Margin % Range Over the Past 10 Years
Min: -36735 Med: -2248.06 Max: -622.24
Current: -622.31

During the past 7 years, the highest FCF Margin % of Imagion Biosystems was -622.24%. The lowest was -36735.00%. And the median was -2248.06%.

ASX:IBX's FCF Margin % is ranked worse than
90.05% of 221 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.47 vs ASX:IBX: -622.31

Imagion Biosystems FCF Margin % Historical Data

The historical data trend for Imagion Biosystems's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagion Biosystems FCF Margin % Chart

Imagion Biosystems Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,020.44

-2,248.06

-2,269.10

-1,814.16

-622.24

Imagion Biosystems Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial									-7,117.19	-1,883.08	-1,717.31	-875.94	-363.81

Competitive Comparison of Imagion Biosystems's FCF Margin %

For the Diagnostics & Research subindustry, Imagion Biosystems's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imagion Biosystems's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's FCF Margin % falls into.

Imagion Biosystems FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Imagion Biosystems's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8.506	/	1.367
	=	-622.24 %

Imagion Biosystems's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.463	/	0.677
	=	-363.81 %

Imagion Biosystems FCF Margin % Related Terms

Thank you for viewing the detailed overview of Imagion Biosystems's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Imagion Biosystems (ASX:IBX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.imagionbiosystems.com

Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems (ASX:IBX) Headlines

No Headlines